<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60392">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01905735</url>
  </required_header>
  <id_info>
    <org_study_id>SLSGB-01</org_study_id>
    <nct_id>NCT01905735</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>A Multicentric,Double-blind,Placebo Controlled,Phase-2 Study to Assess the Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healthcare Homoeo Charitable Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healthcare Homoeo Charitable Society</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the purpose  of the study is to assess the safety and efficacy of  commonly used Homeopathic
      medicine Rhustoxicodendron in 30 potency in the treatment of Rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      it is a multicenter phase 2 ,double blind study in patient with active Rheumatoid arthritis
      ,there are 2 group in the study A and B ,where group A receive Rhustoxicodendron in 30
      potency the first dose will administered orally (1/2 ml)after the completion of case taking
      ,and repeated every 7th day for 5 month and on the other hand group B receive placebo orally
      in (1/2 ml) at same interval for same period .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subject With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR 20/50/70 Responders).</measure>
    <time_frame>6 weeks upto 24 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of subject with ACR criteria improvement consisting of ACR 20,ACR50,ACR70 reduction in tender and swollen joint counts and 20%,50%,70% improvement respectively in 3 of the following 5 criteria .
physician global assessment of disease activity's.
patient global assessment of disease activity's.
subject assessment of pain
subject assessment of function disability via health assessment questionnaire[HAQ]
acute phase reactant ESR every 6 weeks upto 24 week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline in tender joint count.</measure>
    <time_frame>6 weeks upto 24 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline in swollen joint.</measure>
    <time_frame>6 weeks upto 24 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline in physician global assessment of disease activity.</measure>
    <time_frame>every 6 weeks upto 24 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>mean change from baseline in physician assessment of disease activity via visual analog scale(0-100 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline in patient global assessment of disease .</measure>
    <time_frame>6 weeks upto 24 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>mean change from baseline in patient global assessment of disease via visual analog scale(0-100 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline in subject assessment of pain using VAS from 0-100 mm</measure>
    <time_frame>6 weeks upto 24 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline in ESR</measure>
    <time_frame>6 weeks upto 24 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline in disability index of the health assessment Questionnaire (HAQ)</measure>
    <time_frame>6 weeks upto 24 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis.</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1/2 ml of dispensing alcohol administered orally at every 7 day for 5 month .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhustoxicodendron 30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rhustoxicodendron 30</intervention_name>
    <description>1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.</description>
    <arm_group_label>Rhustoxicodendron 30</arm_group_label>
    <other_name>poison ivy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>dispensing alcohol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  those who will provide written consent to participate in the study

          -  patient willing to turn up for 7th day follow up

          -  patient who are willing and compliance to the study

          -  those who are between 25 to 60 years .

          -  patient who are willing and compliance to the study .

          -  ESR more then 28 mm.

        Exclusion Criteria:

          -  Participating as a subject in any other clinical research study.

          -  Children below the age of 25years.

          -  Female subject who are pregnant or planning for pregnancy within 6 month.

          -  History of seizures

          -  Breast feeding women's.

          -  Patient on treatment for life threatening illness like cancer aids etc.

          -  Patient should not have any congenital abnormality or patient should not have
             undergone any operative procedure as consequences of RA.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ravinder kochhar, MD hom</last_name>
    <role>Principal Investigator</role>
    <affiliation>Healthcare Homoeo Charitable Society</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mukesh k singh, B.H.M.S</last_name>
    <role>Study Director</role>
    <affiliation>health care homoeo charitable society</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>seenia sharma, B.H.M.S</last_name>
    <phone>0091-7837144332</phone>
    <email>drseeniasharma@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mukesh k singh, B.H.M.S</last_name>
    <phone>0091-9463131239</phone>
    <email>drmukeshkrsingh@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kochhar Clinic</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>seenia sharma, B.H.M.S</last_name>
      <phone>0091-7837144332</phone>
      <email>drseeniasharma@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>mukesh k singh, B.H.M.S</last_name>
      <phone>0091-9463131239</phone>
      <email>drmukeshkrsingh@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>seenia sharma, B.H.M.S</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>kuljinder kaur, B.H.M.S</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gupta Homoeo Clinic</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mohit gupta, B.H.M.S</last_name>
      <phone>0091-9212580805</phone>
      <email>dr.mohitgupta@yahoo.in</email>
    </contact>
    <investigator>
      <last_name>mohit gupta, B.H.M.S</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>bhuwnesh goyal, B.A.M.S</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>prateek singh, B.H.M.S</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 1, 2013</lastchanged_date>
  <firstreceived_date>July 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Healthcare Homoeo Charitable Society</investigator_affiliation>
    <investigator_full_name>ravinder kochhar</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>RA</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
